GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keymed Biosciences Inc (HKSE:02162) » Definitions » Asset Turnover

Keymed Biosciences (HKSE:02162) Asset Turnover : 0.01 (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Keymed Biosciences Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Keymed Biosciences's Revenue for the six months ended in Jun. 2024 was HK$58.87 Mil. Keymed Biosciences's Total Assets for the quarter that ended in Jun. 2024 was HK$4,171.89 Mil. Therefore, Keymed Biosciences's Asset Turnover for the quarter that ended in Jun. 2024 was 0.01.

Asset Turnover is linked to ROE % through Du Pont Formula. Keymed Biosciences's annualized ROE % for the quarter that ended in Jun. 2024 was -23.75%. It is also linked to ROA % through Du Pont Formula. Keymed Biosciences's annualized ROA % for the quarter that ended in Jun. 2024 was -17.38%.


Keymed Biosciences Asset Turnover Historical Data

The historical data trend for Keymed Biosciences's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keymed Biosciences Asset Turnover Chart

Keymed Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
- - 0.05 0.02 0.09

Keymed Biosciences Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 - 0.08 0.01 0.01

Competitive Comparison of Keymed Biosciences's Asset Turnover

For the Biotechnology subindustry, Keymed Biosciences's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Keymed Biosciences's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Keymed Biosciences's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Keymed Biosciences's Asset Turnover falls into.



Keymed Biosciences Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Keymed Biosciences's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=387.302/( (4391.275+4247.058)/ 2 )
=387.302/4319.1665
=0.09

Keymed Biosciences's Asset Turnover for the quarter that ended in Jun. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Jun. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Jun. 2024 ))/ count )
=58.868/( (4247.058+4096.728)/ 2 )
=58.868/4171.893
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Keymed Biosciences  (HKSE:02162) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Keymed Biosciences's annulized ROE % for the quarter that ended in Jun. 2024 is

ROE %**(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=-725.042/3052.4495
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-725.042 / 117.736)*(117.736 / 4171.893)*(4171.893/ 3052.4495)
=Net Margin %*Asset Turnover*Equity Multiplier
=-615.82 %*0.0282*1.3667
=ROA %*Equity Multiplier
=-17.38 %*1.3667
=-23.75 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2024) net income data. The Revenue data used here is two times the semi-annual (Jun. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Keymed Biosciences's annulized ROA % for the quarter that ended in Jun. 2024 is

ROA %(Q: Jun. 2024 )
=Net Income/Total Assets
=-725.042/4171.893
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-725.042 / 117.736)*(117.736 / 4171.893)
=Net Margin %*Asset Turnover
=-615.82 %*0.0282
=-17.38 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2024) net income data. The Revenue data used here is two times the semi-annual (Jun. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Keymed Biosciences Asset Turnover Related Terms

Thank you for viewing the detailed overview of Keymed Biosciences's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Keymed Biosciences Business Description

Traded in Other Exchanges
N/A
Address
No. 18 BioTown Middle Road, Building D2, Tianfu International BioTown, Chengdu, Sichuan, CHN, 610219
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
Executives
Chen Bo 2201 Interest of corporation controlled by you
Eagle Hero Management Limited 2101 Beneficial owner
Trident Trust Company (hk) Limited 2301 Trustee
Moonshot Holdings Limited 2101 Beneficial owner
Hh Kny Holdings Limited
Hillhouse Investment Management, Ltd.
Boyu Capital Group Holdings Ltd
Xyxy Holdings Ltd.
Tong Xiaomeng

Keymed Biosciences Headlines

No Headlines